Filing Flows › Rigel Pharmaceuticals (RIGL) › Q2 2025
Rigel Pharmaceuticals (RIGL) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Rigel Pharmaceuticals (RIGL) reported revenue of $102M for the second quarter 2025 (Q2 2025), +176% from a year earlier and +91% from the quarter before. Operating margin was 60.1%, net earnings $59.6M (58.6% of revenue).
Rigel Pharmaceuticals, Q2 2025: revenue $102M (+176% year over year), operating margin 60.1%, net earnings $59.6M, operating cash flow $30.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $102M | +91% | +176% |
| Operating profit | $61.1M | +378% | 137× |
| Net earnings | $59.6M | +421% | — |
| Operating cash flow | $30.5M | — | 101× |
What changed
Revenue was $101.7M in Q2 2025, up 176% year over year and up 91% from the previous quarter. Product sales, net was the largest line at 58% of revenue. Product sales, net added $25.5M year over year (up 76%), 39% of the total change. Delivery of drug supplies, royalties and others declined 19%.
Operating profit was $61.1M, a 60.1% margin (up 58.9 points year over year). Of the extra revenue versus a year earlier, 94% reached operating profit, above the 1% margin then. Total costs grew 12% against revenue growth of 176%. The fastest-growing cost line was Cost of revenue (+60%). Net earnings were $59.6M. The effective tax rate was 0.6%.
Operating cash flow was $30.5M (up 10012% year over year), 51% of net earnings. Non-cash charges added back $607K of depreciation and amortization and $3.3M of share-based compensation. Working capital and other items used $33.0M.
Questions
What was Rigel Pharmaceuticals' revenue in the second quarter 2025?
Rigel Pharmaceuticals (RIGL) reported revenue of $102M for the second quarter 2025 (Q2 2025), +176% from a year earlier and +91% from the quarter before.
Was Rigel Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $61.1M (60.1% of revenue) and net earnings $59.6M.